12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CV9104: Phase I/IIb started

CureVac began a double-blind, placebo-controlled Phase I/IIb trial to evaluate intradermal CV9104 in up to 200 chemotherapy-naïve patients with asymptomatic or minimally symptomatic...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >